Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Baptist Health South Florida
Essen Biotech
Essen Biotech
St. Jude Children's Research Hospital
Stemline Therapeutics, Inc.
Australian & New Zealand Children's Haematology/Oncology Group
Eli Lilly and Company
Eli Lilly and Company
PharmaMar
University Hospital, Basel, Switzerland
Northwell Health
Northwell Health
Northwell Health
BeiGene
Aminex Therapeutics, Inc.
Novelwise Pharmaceutical Corporation
Basilea Pharmaceutica
NaviFUS Corporation
The First Affiliated Hospital with Nanjing Medical University
TVAX Biomedical
Bristol-Myers Squibb
Boston Scientific Corporation
Accendatech USA Inc.
Proximagen, LLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
University of Regensburg
Celgene
AHS Cancer Control Alberta
National Institutes of Health Clinical Center (CC)
Hadassah Medical Organization
BBB-Therapeutics B.V.
INSYS Therapeutics Inc
Visualase, Inc.